Quest Diagnostics climbs as Q2 earnings top estimates, guidance raised
Seeking Alpha ·
Quest Diagnostics ( DGX ) shares climbed about 11% on Thursday after the diagnostic testing company reported second-quarter results that topped Wall Street estimates and lifted its full-year 2026 guidance above consensus. The company posted adjusted earnings of $3.12 per share, beating
AI 시장 분석
Quest Diagnostics (DGX) saw a 2Q earnings beat, with a higher than consensus 2026 end-of-year guide, driving an 11% stock gain.
상승 영향
- Medical Testing — Quest Diagnostics' (DGX) 2Q earnings beat and a higher than consensus 2026 end-of-year guide suggest a strong growth potential in the medical testing sector.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 47% · Bearish (Short) 53%
567 participants
Related News
- Gentherm raises 2026 outlook while targeting $3.5B+ revenue by 2030 through Modine combination
- Charter Communications Q2 2026 Earnings Preview
- Medpace leads a rally in CRO space after Q2 beat
- Canadian National Railway Q2 2026 Earnings Preview
- House narrowly passes $1.15 trillion defense bill as Senate hurdles remain
- Nexstar slips as state AGs accuse the company of violating the Tegna integration order
